Seroatlas · Human Serome Atlas

PRPF19

Pre-mRNA-processing factor 19

Also known as: hPSO4, NMP200, PRP19, PRP19_HUMAN, PSO4, SNEV, UBOX4

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q9UMS4
Gene
PRPF19
Ensembl
ENSG00000110107
Chromosome
11
Canonical length
504 aa
Protein class
Enzymes, Plasma proteins, Predicted intracellular proteins
Subcellular location
Nuclear speckles
Quaternary structure
Homotetramer

OverviewNCBI Gene

Enables identical protein binding activity and ubiquitin-ubiquitin ligase activity. Involved in several processes, including DNA damage checkpoint signaling; mRNA splicing, via spliceosome; and protein K63-linked ubiquitination. Acts upstream of or within protein polyubiquitination. Located in cytoplasm; nuclear lumen; and site of double-strand break. Part of Prp19 complex and U2-type catalytic step 2 spliceosome. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

504 residues, UniProt reviewed canonical sequence.

>Q9UMS4|PRPF19
     1  MSLICSISNE VPEHPCVSPV SNHVYERRLI EKYIAENGTD PINNQPLSEE QLIDIKVAHP
    61  IRPKPPSATS IPAILKALQD EWDAVMLHSF TLRQQLQTTR QELSHALYQH DAACRVIARL
   121  TKEVTAAREA LATLKPQAGL IVPQAVPSSQ PSVVGAGEPM DLGELVGMTP EIIQKLQDKA
   181  TVLTTERKKR GKTVPEELVK PEELSKYRQV ASHVGLHSAS IPGILALDLC PSDTNKILTG
   241  GADKNVVVFD KSSEQILATL KGHTKKVTSV VFHPSQDLVF SASPDATIRI WSVPNASCVQ
   301  VVRAHESAVT GLSLHATGDY LLSSSDDQYW AFSDIQTGRV LTKVTDETSG CSLTCAQFHP
   361  DGLIFGTGTM DSQIKIWDLK ERTNVANFPG HSGPITSIAF SENGYYLATA ADDSSVKLWD
   421  LRKLKNFKTL QLDNNFEVKS LIFDQSGTYL ALGGTDVQIY ICKQWTEILH FTEHSGLTTG
   481  VAFGHHAKFI ASTGMDRSLK FYSL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PRPF19 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.31
Highest tissue expression
103 nTPM

Expression across tissuesHPA

Tissue

  • cerebral cortex: 103 nTPM
  • cerebellum: 91 nTPM
  • hypothalamus: 86 nTPM
  • parathyroid gland: 75 nTPM
  • thymus: 73 nTPM
  • esophagus: 73 nTPM

Single-cell type

  • migrating cytotrophoblasts: 123 nCPM
  • cytotrophoblasts: 118 nCPM
  • extravillous trophoblasts: 100 nCPM
  • esophageal basal cells: 92 nCPM
  • erythrocyte progenitors: 73 nCPM
  • megakaryocytes: 68 nCPM

Immune cell

  • classical monocyte: 7.9 nTPM
  • basophil: 4.2 nTPM
  • plasmacytoid DC: 3.9 nTPM
  • intermediate monocyte: 3.8 nTPM
  • myeloid DC: 3.6 nTPM
  • gdT-cell: 2.4 nTPM

Brain region

  • cerebral cortex: 147 nTPM
  • hypothalamus: 138 nTPM
  • pons: 134 nTPM
  • basal ganglia: 127 nTPM
  • white matter: 113 nTPM
  • midbrain: 111 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about PRPF19.

Disease | GeneticClinVar

1 pathogenic / likely-pathogenic of 58 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.11
gnomAD pLI
1
gnomAD missense Z
3.74
DepMap mean gene effect
-2.38
DepMap dependency class
pan

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of PRPF19 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PRPF19 as an antibody target. Whether an autoantibody or antibody against PRPF19 could matter depends on whether native PRPF19 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PRPF19 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label PRPF19 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/PRPF19. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...